DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD  20857

NDA 20-441/S-018, 20-746/S-011 and 20-929/S-015

AstraZeneca LP
1800 Concord Pike
P.O. Box 8355
Wilmington, DE  19803-8355

Attention:  Christopher Blango
Director, Regulatory Affairs

Dear Mr. Blango:

Please refer to your supplemental new drug applications dated March 25, 2003, received March 26, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pulmicort Turbuhaler (budesonide inhalation powder), Rhinocort Aqua (budesonide) Nasal Spray and Pulmicort Respules (budesonide inhalation suspension), respectively.

These “Changes Being Effected” supplemental new drug applications provide for revisions to the Drug Interactions subsection of the PRECAUTIONS section of the package insert.

We completed our review of these supplemental new drug applications.  They are approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on March 25, 2003.

We remind you that you must submit patent information on form FDA 3542, Patent Information Submitted Upon and After Approval of an NDA or Supplement, within 30 days of the date of this letter as required by 21 CFR 314.53(c)(2)(ii) and 314.53(d)(2) at the address provided by 21 CFR 314.53(d)(4).  The form may be obtained at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html.  To expedite review of this patent declaration form, we request you submit an additional copy of the form to these applications and to the Center for Drug Evaluation and Research "Orange Book" staff at

Food and Drug Administration
Office of Generic Drugs, HFD-610
Orange Book Staff
7500 Standish Place
Metro Park North II
Rockville, MD 20855-2773

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:
We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Colette Jackson, Regulatory Project Manager, at (301) 827-5584.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Division Director
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------
Badrul Chowdhury
9/26/03 04:57:59 PM